193 related articles for article (PubMed ID: 8962277)
41. CD25-targeted therapy revisited.
Kupiec-Weglinski JW
Transplantation; 2000 Feb; 69(3):328-30. PubMed ID: 10706037
[No Abstract] [Full Text] [Related]
42. Cellular adhesion molecules in transplantation.
Rodriguez-Iturbe B
Transplant Proc; 1996 Dec; 28(6):3285-9. PubMed ID: 8962274
[No Abstract] [Full Text] [Related]
43. The expression patterns of CD44 and CD45RB on peripheral blood T lymphocytes in the rejection of allogeneic murine skin transplantation.
Yang J; Ahn C; Jung HK; Kim EK; Kim JY; Kim YS; Han JS; Kim S; Lee JS
Transpl Immunol; 2003; 11(2):197-206. PubMed ID: 12799204
[TBL] [Abstract][Full Text] [Related]
44. Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.
Kahan BD
Transplant Proc; 2009 Dec; 41(10):3975-4020. PubMed ID: 20005335
[No Abstract] [Full Text] [Related]
45. New monoclonal antibodies.
Costanzo MR
Curr Opin Cardiol; 1996 Mar; 11(2):204-7. PubMed ID: 8736692
[TBL] [Abstract][Full Text] [Related]
46. [Organ transplantation: epidemiological and immunological aspects; principles of treatment and surveillance; complications and prognosis; ethical and legal aspects].
Lebranchu Y; Sirinelli A; Wolf P; Mornex JF
Rev Prat; 2004 Dec; 54(20):2295-304; quiz 2304. PubMed ID: 15736544
[No Abstract] [Full Text] [Related]
47. Counting of lymphocyte subpopulations using standard versus low-dose antiCD3 monoclonal antibody treatment.
González-Martínez F; Curi L; Núñez H; González AC; Orihuela N; González G; Orihuela S
Transplant Proc; 2004; 36(6):1659-60. PubMed ID: 15350443
[TBL] [Abstract][Full Text] [Related]
48. Induction of immunological tolerance using monoclonal antibodies: applications to organ transplantation and autoimmune disease.
Bach JF
C R Biol; 2006 Apr; 329(4):260-2. PubMed ID: 16644496
[TBL] [Abstract][Full Text] [Related]
49. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
[TBL] [Abstract][Full Text] [Related]
50. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection: analysis beyond 4 years.
Sharma LC; Muirhead N; Lazarovits AI
Transplant Proc; 1997; 29(1-2):323-4. PubMed ID: 9123021
[No Abstract] [Full Text] [Related]
51. Use of locally injected anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
Ippoliti G; Fronterrè A
Transplant Proc; 1987 Feb; 19(1 Pt 3):2579-80. PubMed ID: 3274568
[No Abstract] [Full Text] [Related]
52. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394
[TBL] [Abstract][Full Text] [Related]
53. Orthoclone OKT3: an overview of the monoclonal antibody and the nursing considerations it presents.
Pezze JL; Whiteman K
Crit Care Nurse; 1991 May; 11(5):98-102, 104-7. PubMed ID: 1902767
[No Abstract] [Full Text] [Related]
54. [Treatment of kidney graft rejection with a monoclonal antibody (Orthoclone OKT-3)].
Ladefoged SD; Friedberg M; Glenthøj A
Ugeskr Laeger; 1988 Nov; 150(48):2974-6. PubMed ID: 3144080
[No Abstract] [Full Text] [Related]
55. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U
Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic use of the monoclonal antibody Orthoclone OKT3.
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-58. PubMed ID: 3105133
[No Abstract] [Full Text] [Related]
57. Treatment of acute kidney allograft rejection with the nonmitogenic CD3 mAb CLB T3/4.A (IgA-CD3): absence of a correlation of clinical responsiveness with inhibition of lymphocyte reactivity in vitro.
Meijer RT; Yong SL; Surachno S; ten Berge IJ; Schellekens PT
Transplant Proc; 2001; 33(1-2):1229-30. PubMed ID: 11267271
[No Abstract] [Full Text] [Related]
58. CD3-specific antibody-induced active tolerance: from bench to bedside.
Chatenoud L
Nat Rev Immunol; 2003 Feb; 3(2):123-32. PubMed ID: 12563296
[TBL] [Abstract][Full Text] [Related]
59. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
[No Abstract] [Full Text] [Related]
60. Immunobiology of solid organ transplantation.
Turvey SE; Wood KJ
Int Surg; 1999; 84(4):279-90. PubMed ID: 10667806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
